language_icon
EN
HI

Beta Drugs Share price

BETA

1330.1

0.00 (0.00%)
Last updated on 30 Apr, 2026 | 15:31 IST
Today's High

1367.60

Today's Low

1300.10

52 Week Low

990.10

52 Week High

2000.00

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Beta Drugs Chart

Beta Drugs Share Key Metrics

Volume
9348.00
Market Cap
1348.31 CR
LTQ@LTP
6@1330.10
ATP
1334.13
Var Margin
18.05 %
Circuit Range
1044.3-1566.3
Delivery %
63.38 %
Value
1.25 CR
ASM/GSM
No
Market Lot
1

Summary

Beta Drugs share price stands at ₹1330.1 at 30 Apr, 2026 | 15:31. The stock Beta Drugs intraday movement has stayed between ₹1300.10 and ₹1367.60, while on a 52-week basis it has fluctuated from ₹990.10 to ₹2000.00.
In terms of trading activity, Beta Drugs has recorded a volume of 9348 shares. The Beta Drugs has a market cap of ₹10136890. The stock’s Average Traded Price (ATP) stands at ₹133413, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 6, 133010.
The Beta Drugs operates within a circuit range of ₹1044.3-1566.3 – ₹1044.3-1566.3, with a Value of ₹1.25 CR. The Delivery Percentage for the day is 63.38%. Additionally, Beta Drugs currently falls under the No framework, and trades with a market lot size of 1.

Beta Drugs Fundamentals

View More
P/E Ratio

32.68

P/B Ratio

6.73

Div. Yield

0

Sector P/E

65.48

Sector P/B

3.51

Sec. Div. Yield

0.57

Beta Drugs Resistance and Support

Pivot 1332.6

Resistance

First Resistance

1365.1

Second Resistance

1400.1

Third Resistance

1432.6

Support

First Support

1297.6

Second Support

1265.1

Third Support

1230.1

Beta Drugs Shareholding Pattern

View More
  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

64.63%

Mutual Fund

0%

Insurance

0%

Foreign Institutional Investors

1.16%

Domestic Institutional Investors

2.14%

Retail

32.07%

Others

0%

Total Promoters
MAR '26
64.63%

Beta Drugs Corporate Actions

DateAgenda
2026-02-14Quarterly Results
2026-01-09Others

Beta Drugs News

Beta Drugs Limited (BETA)

Beta Drugs Limited allotted 283,668 equity shares on April 25, 2026, via a preferential issue. This increased the company's paid-up capital to ₹10.42 crores, with shares issued at ₹1,712.49 each to 33 investors.
Apr 25 2026 14:04:00

Beta Drugs Limited (BETA)

Beta Drugs' board approved the allotment of 2,83,668 equity shares. These shares, priced at ₹1,712.49 each (including a premium of ₹1,702.49), are issued to facilitate the acquisition of Nivian Lifesciences Private Limited.
Apr 25 2026 13:04:00

Beta Drugs Limited (BETA)

Beta Drugs expands international market access with key regulatory milestones in Azerbaijan and the Philippines. The company expects GMP approval in 1-2 months for Azerbaijan and secured product registrations for 2 generic brands in the Philippines, strengthening export sales.
Apr 22 2026 09:04:00

Beta Drugs Limited (BETA)

Beta Drugs expands international market access with key regulatory milestones in Azerbaijan and the Philippines. The company expects GMP approval in 1-2 months for Azerbaijan and secured product registrations for 2 generic brands in the Philippines, strengthening export sales.
Apr 22 2026 09:04:00

Beta Drugs Limited (BETA)

Beta Drugs clarified significant share price movement. The company confirmed no undisclosed price-sensitive information and stated the movement is purely market-driven.
Apr 07 2026 10:04:00

Beta Drugs Limited (BETA)

Beta Drugs clarified its shareholding pattern after a preferential issue, with promoter holding decreasing from 64.63% to 59.10%. Institutional investors increased their stake from 3.43% to 9.14%. The clarification addresses observations from NSE regarding an Extra Ordinary General Meeting notice.
Apr 03 2026 10:04:00

Beta Drugs Limited (BETA)

Beta Drugs clarified its shareholding pattern after a preferential issue, with promoter holding decreasing from 64.63% to 59.10%. Institutional investors increased their stake from 3.43% to 9.14%. The clarification addresses observations from NSE regarding an Extra Ordinary General Meeting notice.
Apr 03 2026 10:04:00
Read More

About Beta Drugs

NSE : 759842  
BSE : 0  
ISIN : INE351Y01019  

The Company was incorporated as ?Beta Drugs Private limited? at Himachal Pradesh as a private limited company under the provisions of the Companies Act 1956 vide Certificate of Incorporation dated September 21 2005 bearing Corporate Identification Number U24230HP2005PTC28969 issued by Registrar of Companies Punjab Himachal Pradesh and Chandigarh. Subsequently the Company was converted in to public limited company pursuant to Shareholders Resolution passed at the Extra-Ordinary General Meeting of the Company held on July 24 2017 and the name of the Company was changed to ?Beta Drugs Limited? pursuant to issuance of fresh Certificate of Incorporation consequent upon conversion of Company from Private to Public Limited dated August 11 2017 issued by the Registrar of Companies Himachal Pradesh. The Corporate Identification Number of the Company is U24230HP2005PLC028969.KEY EVENTS AND MILESTONES IN THE HISTORY OF THE COMPANY2005 -Incorporation of the Company as Beta Drugs Private Limited2014 -Vijay Kumar Batra existing promoter took over the Company2015-ISO: 9001:2008 Certification for manufacturing and supply of Pharmaceutical products such as Oncology  Sterile Injections and Lyophilized Injections and Oncology solid oral medication tablets and capsules-Certificate of Good Manufacturing Practice from Health and Family Welfare Department Himachal Pradesh2016-Certificate of Good Manufacturing Practice from Republic of Kenya2017 -Conversion of Company into Public Limited Company

Read More

Beta Drugs Management

NamePosition
Rahul BatraChairman & Managing Director
Varun BatraJoint Managing Director
View More

Beta Drugs FAQs

The Buying Price of Beta Drugs share is 1330.1 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Beta Drugs stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Beta Drugs, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Beta Drugs shares is 32.68. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Beta Drugs shares is 6.73. Useful to assess the stock's value relative to its book value.

To assess Beta Drugs’s valuation compare Sector P/E, P/B which are 65.48 & 3.51 with sector averages, along with growth rates and financial metrics.

The Market Cap of Beta Drugs is 1348.31 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Beta Drugs share price is 2000.00 & 990.10. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Beta Drugs belongs to the Healthcare sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost